J.P. Morgan Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $13

Futu NewsNov 9 22:32 · Ratings

Hold Recommendation for Vir Biotechnology Amid Cautious Optimism on Infectious Disease and Oncology Prospects

TipRanksNov 9 21:35

Analysts Conflicted on These Healthcare Names: Vir Biotechnology (VIR) and Moderna (MRNA)

TipRanksNov 6 16:30 · Ratings

Vir Biotechnology | 10-Q: Q3 2024 Earnings Report

SECNov 5 05:16 · Announcements

Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Dow JonesNov 4 19:31 · Ratings

Vir Biotechnology's Promising Hepatitis Programs and Strategic FDA Alignment Justify Buy Rating

TipRanksNov 4 19:15 · Ratings